Needham Reiterates Buy on Biogen, Maintains $305 Price Target
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Ami Fadia has reiterated a 'Buy' rating on Biogen (NASDAQ:BIIB) and maintained a price target of $305.
October 26, 2023 | 10:39 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Needham analyst has reiterated a 'Buy' rating on Biogen and maintained a price target of $305.
The reiteration of a 'Buy' rating by a Needham analyst and the maintenance of a $305 price target indicates a positive outlook for Biogen. This could potentially lead to an increase in investor confidence and a positive impact on the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100